John Olkowski, MD
Ophthalmology · Honolulu, HINPI 1396897427
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Glaukos Corporation accounts for 67.9% of it on its own, with 24 other manufacturers making up the rest. 2025 is the largest year on record at $11,327, more than ten times the $882 reported in 2019.
Across 145 payments — averaging $102.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$10K
- Alcon$1K
- Dompe US, Inc.$537
- Kowa Pharmaceuticals America, Inc.$282
- Bausch & Lomb, A Division Of Bausch Health US, LLC$275
- Oyster Point Pharma, Inc.$274
- plus $2K from 19 others
What the payments were for
- Consulting fees$6,90046%
- Travel & lodging$2,49517%
- Food & beverage$4,64831%
- Education$180%
- Entertainment$160%
- Other$8386%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 18 | $10,121 |
| Alcon | 13 | $1,477 |
| Dompe US, Inc. | 10 | $537 |
| Kowa Pharmaceuticals America, Inc. | 17 | $282 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $275 |
| Oyster Point Pharma, Inc. | 11 | $274 |
| Sun Pharmaceutical Industries Inc. | 9 | $254 |
| Amgen(2 entities) | 7 | $221 |
| Rxsight Inc | 4 | $216 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $207 |
| Mallinckrodt Hospital Products Inc. | 4 | $188 |
| Sight Sciences, Inc. | 1 | $135 |
| Aerie Pharmaceuticals, Inc. | 6 | $108 |
| Bausch & Lomb Americas Inc. | 6 | $106 |
| AbbVie(2 entities) | 4 | $89 |
| Novartis | 4 | $74 |
| Quidel Corporation | 3 | $67 |
| Harrow Eye, LLC | 2 | $62 |
| Eyevance Pharmaceuticals LLC | 4 | $57 |
| Kala Pharmaceuticals, Inc. | 3 | $54 |
| Shire North American Group Inc | 2 | $33 |
| Biotissue Holdings Inc. | 1 | $30 |
| Mallinckrodt Enterprises LLC | 1 | $21 |
| Optos, Inc. | 1 | $16 |
| Omeros Corporation | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epioxa$7,407
- Travoprost Intraocular Implant - iDose$1,476
- Unity$983
- KXL System$863
- Oxervate$347
- ARGOS$146
- OMNI(R) SURGICAL SYSTEM (US)$135
- ACTHAR$125
- RXSIGHT CONTACT LENS$120
- RXSIGHT INJECTOR CARTRIDGE$120
- RXSIGHT INJECTOR HANDPIECE$120
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$120
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$120
- LOTEMAX$112
- Clareon$111
- Tecnis Multifocal Family of 1-piece IOLS$104
- Catalys Laser System$104
How this compares
$14,915 in reported general payments places this provider in the 85th percentile of 120 ophthalmology providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 56 | $77,392 |
| RocklatanNetarsudil Mesylat/Latanoprost | 59 | $22,454 |
| RhopressaNetarsudil Mesylate | 19 | $17,292 |
| Loteprednol Etabonate | 103 | $16,895 |
| MieboPerfluorohexyloctane/Pf | 20 | $15,226 |
| ProlensaBromfenac Sodium | 41 | $14,477 |
| Prednisolone Acetate | 297 | $14,418 |
| LumiganBimatoprost | 15 | $8,967 |
| CombiganBrimonidine Tartrate/Timolol | 18 | $8,238 |
| VyzultaLatanoprostene Bunod | 16 | $7,049 |
| Latanoprost | 224 | $4,919 |
| MoxifloxacinMoxifloxacin Hcl | 161 | $4,433 |
| Brimonidine Tartrate | 32 | $3,375 |
| Bromfenac Sodium | 15 | $3,006 |
| Fluorometholone | 16 | $1,309 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $89 | $94,59789 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $108 | $39,74678 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Prolensa | $275 | $31,371144 claims |
| Bausch & Lomb Americas Inc.Miebo, Vyzulta | $106 | $22,27436 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 120 ophthalmology providers in Hawaii.
Other ophthalmology in Honolulu
- Neda NikpoorHonolulu$293K
- Carlton YuenHonolulu$175K
- Alan FaulknerHonolulu$135K
- Michael BennettHonolulu$108K
- Jeffrey PetersonHonolulu$77K
- Rupa WongHonolulu$72K
- Jon PortisHonolulu$20K
- Tyrie JenkinsHonolulu$19K
- Claudia HootenHonolulu$14K
- Kenneth ChangHonolulu$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.